Port Site Infiltration With Bupivacaine for Reduction of Postoperative Pain in Woman Undergoing Gynecologic Laparoscopy: A Randomized, Factorial, Double-Blind, Controlled Trial
Overview
- Phase
- Phase 4
- Intervention
- Bupivacaine Hydrochloride
- Conditions
- Postoperative Pain Score
- Sponsor
- Rajavithi Hospital
- Enrollment
- 100
- Locations
- 1
- Primary Endpoint
- Postoperative pain after surgery
- Status
- Completed
- Last Updated
- 5 years ago
Overview
Brief Summary
To comparison of efficacy of Bupivacaine for relief postoperative pain in women undergoing laparoscopic gynecologic surgery
Detailed Description
Gynecologic laparoscopic procedures have become more common nowadays because of their benefits in less tissue trauma, less perioperative morbidity and shorter hospital stays compared with laparotomy. But postoperative pain still be the most concerning problems including discomfort at incision sites, Pain due to pneumoperitoneum stretching the intraabdominal cavity and dissection of the abdominal and pelvic viscera. Visceral pain is at maximal intensity during the first postoperative hours and is exacerbated by coughing, respiratory movements, and mobilization. Because the pain comprises of several factors, multimodal analgesic techniques are needed for effective postoperative analgesia and brought to this study to compare efficacy of Bupivacaine for pain relief postoperatively in women undergoing gynecologic laparoscopic surgery divided into 4 groups including preincision and preclosure Bupivacaine injection collated with placebo group. The result is measurement in postoperative pain score and amount of drug that using to reduce pain
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patient who undergoing gynecologic laparoscopic surgery
- •Patient who agrees to participate in this study
- •Patient able to speak and understand Thai
- •Patient able to complete the questionnaire
Exclusion Criteria
- •Patient with history of allergy in any kind anesthetic drug
- •Patient who pregnant
- •Patient who sign for single port gynecologic laparoscopic surgery or NOTE surgery
- •Patient whom the surgery is withhold or canceled
- •Patient whom the surgery is converted to laparotomy
Arms & Interventions
placebo group
0.9%Nacl (Placebo) 10 ml were port site infiltration prior skin incision and prior skin closure Drug: 0.9%Nacl Other Name: NSS
Intervention: Bupivacaine Hydrochloride
Preincision Bupivacaine
0.5% bupivacaine 10 ml (50 mg) were port site infiltration prior skin incision and 0.9%Nacl (Placebo) 10 ml were port site infiltration prior skin closure Drug: 0.5% bupivacaine 10 ml (50 mg) Other Name: Marcaine 0.9%Nacl (Placebo) 10 ml Other Name: NSS
Intervention: Bupivacaine Hydrochloride
Preclosure bupivacaine
0.9%Nacl (Placebo) 10 ml were port site infiltration prior skin incision and 0.5% bupivacaine 10 ml (50 mg) were port site infiltration prior skin closure Other Name: Marcaine
Intervention: Bupivacaine Hydrochloride
Bupivacaine group
0.5% bupivacaine 10 ml (50 mg) were port site infiltration prior skin incision and 0.5% bupivacaine 10 ml (50 mg) were port site infiltration prior skin closure Other Name: Marcaine
Intervention: Bupivacaine Hydrochloride
Outcomes
Primary Outcomes
Postoperative pain after surgery
Time Frame: 24-48 hours after surgery
Postoperative pain score in intervention and placebo groups
Secondary Outcomes
- Among of pethidine use(within 48 hours)
- Duration of hospital stay(within 7 days)